Building on our 50 year heritage in respiratory research, we remain relentless in our pursuit to improve the outcomes for patients with asthma and COPD.
Alongside inhaled approaches, where the focus is on helping patients achieve good control of their symptoms, we are developing the next generation of treatments – novel biologics and medicines that target the underlying causes of disease. Beyond asthma and COPD, we are actively exploring treatments for other respiratory diseases, such as idiopathic pulmonary fibrosis and acute lung injury.
In the future, improvements in the treatment of respiratory diseases will come not only from new medicines but also from innovations in patient care, including adherence and treatment personalisation.”
Working in Respiratory R&D
Meet our people and hear what it's like to work in GSK R&D
Explore more features
Inhaler innovation: more than a simple piece of plastic
At first glance, an inhaler may look like a simple piece of plastic. But inside, a complicated process and an internal ‘engine’ operate seamlessly...
An 'everyday' world first in clinical trials
The way we design and carry out clinical trials is being turned on its head by the advent of the Salford Lung Study (SLS).